What vitamin D does, why medical bodies disagree on where "deficiency" begins, who is actually at risk, and why a common GC gene variant nudges measured vitamin D levels modestly without diagnosing deficiency on its own.
Vitamin D is best known for its role in bone health: it helps the gut absorb calcium and phosphate, and without enough of it, bones can become weak or poorly mineralized. It also has roles in muscle function and in modulating the immune system, though the strength of evidence for many of these "extra-skeletal" benefits is much less settled than the classic bone story. Unlike most vitamins, the body can make its own vitamin D: ultraviolet light from the sun converts a compound in the skin into vitamin D3, which the liver then converts into the form that gets measured in a blood test, and the kidney converts a small further amount into the active hormone that does the actual work.
Here is something many people don't realize: there is no single, universally agreed-upon cutoff for "vitamin D deficiency." Two major U.S. bodies use different thresholds, calibrated for different purposes. The Institute of Medicine (now part of the National Academies), reviewing evidence for population-wide dietary requirements, set a level below 30 nmol/L (12 ng/mL) as indicating deficiency risk for essentially everyone, with 30-50 nmol/L (12-20 ng/mL) flagged as a possible risk of inadequacy for some people, and levels at or above 50 nmol/L (20 ng/mL) considered adequate for the general population's bone health. The Endocrine Society's widely-quoted 2011 guidance, aimed at patients already known to be at risk rather than the general population, used a stricter scale: below 20 ng/mL (50 nmol/L) as deficient, 21-29 ng/mL as insufficient, and 30 ng/mL or above as sufficient. A level that framework flags as "insufficient" is, in the Institute of Medicine's framework, often considered adequate — so the same blood test can be read differently depending on which reference range a lab uses.
That disagreement has since narrowed from an unexpected direction. In 2024 the Endocrine Society published a new guideline that stepped away from its own 2011 numbers: it dropped the 30 ng/mL sufficiency target and the deficient/insufficient/sufficient framework, and recommended against routine 25(OH)D testing in the general population, reserving empiric supplementation for specific groups instead. So the "two competing thresholds" story people still repeat online is out of date — one of the two bodies has walked its own numbers back. If you are looking at a result against a 30 ng/mL target, it is worth knowing where that target came from and that its authors no longer stand behind it.
Because sun exposure is the main natural source of vitamin D, people who get little unprotected sun — due to indoor lifestyles, high latitude, winter season, consistently covered skin, or sunscreen use — tend to make less of it. Skin pigmentation matters too: melanin absorbs the ultraviolet light needed for vitamin D synthesis, so people with darker skin generally need more sun exposure to generate the same amount, which is part of why measured vitamin D levels tend to be lower, on average, in people of African ancestry in temperate countries. Other well-established risk factors include older age (skin becomes less efficient at making vitamin D with age), obesity (vitamin D is fat-soluble and gets diluted into a larger volume of body fat), conditions that impair fat absorption (such as celiac disease, Crohn's disease, or prior bariatric surgery), exclusively breastfed infants who aren't given supplemental vitamin D, chronic kidney or liver disease (which impair the conversion steps), and certain medications, including some anticonvulsants, that speed up the breakdown of vitamin D in the body.
Most vitamin D circulating in the blood travels attached to a carrier called vitamin D binding protein, made by the gene GC (its older name, "group-specific component," is a historical holdover). In the largest genetic study of vitamin D levels to date, involving nearly 34,000 people, a variant in this gene, rs2282679, emerged as the single strongest common genetic influence on measured vitamin D levels — more so than variants in the genes that actually build or activate the vitamin. People who carry the variant tend to have somewhat lower measured blood levels of vitamin D and a modestly higher chance of testing as vitamin-D-deficient; in one study, each copy of the risk-associated version was linked to about a 35% higher relative risk of measured deficiency.
It's important to be precise about what that means in practice. This is a population-level statistical association, not a diagnosis. The great majority of the variation in any one person's vitamin D level is driven by sun exposure, diet, body weight, and other behavioral and environmental factors, not by this single gene variant. Carrying the "risk" version of rs2282679 does not mean someone is vitamin-D-deficient, and not carrying it does not mean someone is protected from becoming deficient. The only way to know an individual's actual vitamin D status is a blood test measuring 25-hydroxyvitamin D directly — this genetic variant simply helps explain, at a population level, why measured levels vary somewhat from person to person even under similar sun exposure and diet.
Cutaneous 7-dehydrocholesterol is converted by UVB radiation to previtamin D3, which isomerizes to cholecalciferol (vitamin D3); dietary intake contributes vitamin D3 and D2 (ergocalciferol). Hepatic 25-hydroxylation (principally via CYP2R1) produces 25-hydroxyvitamin D [25(OH)D], the major circulating form and the analyte measured clinically to assess vitamin D status. Renal 1-alpha-hydroxylation (CYP27B1), regulated by parathyroid hormone, serum calcium/phosphate, and fibroblast growth factor 23, produces the active hormone 1,25-dihydroxyvitamin D (calcitriol), which acts through the vitamin D receptor (VDR) to increase intestinal calcium and phosphate absorption and to support bone mineralization; CYP24A1 mediates catabolic inactivation.
The Endocrine Society's 2011 clinical practice guideline (Holick et al., aimed at patients at risk for deficiency) defines 25(OH)D deficiency as below 20 ng/mL (50 nmol/L) and insufficiency as 21-29 ng/mL (52.5-72.5 nmol/L). The Institute of Medicine/National Academy of Medicine's 2011 Dietary Reference Intake framework (aimed at general-population adequacy) instead defines risk of deficiency as 25(OH)D below 30 nmol/L (12 ng/mL) and risk of inadequacy as 30-49 nmol/L (12-20 ng/mL), with levels at or above 50 nmol/L (20 ng/mL) considered sufficient for the general population's bone health. These two frameworks are not interchangeable and are frequently conflated in secondary sources; the difference is large enough that a given 25(OH)D result can be classified as "insufficient" under one framework and "adequate" under the other. The U.S. Preventive Services Task Force does not recommend population-wide screening for vitamin D deficiency in asymptomatic, average-risk adults, citing insufficient evidence that screening improves outcomes; targeted testing in individuals with known risk factors is a separate, more widely supported practice.
Using NHANES 2011-2014 data and the Institute of Medicine thresholds, Herrick et al. (2019, Am J Clin Nutr) estimated that 5.0% (95% CI 4.1-6.2%) of the U.S. population aged 1 year and older was at risk of vitamin D deficiency (25(OH)D <30 nmol/L) and 18.3% (95% CI 16.2-20.6%) at risk of inadequacy (30-49 nmol/L), with substantial disparity by race/ethnicity: risk of deficiency was 17.5% among non-Hispanic Black individuals versus 2.1% among non-Hispanic White individuals, a difference attributed primarily to cutaneous melanin content reducing UVB-driven synthesis rather than to genetic variation at the GC locus.
GC (4q13.3) encodes vitamin D binding protein (DBP), the principal plasma transport protein for 25(OH)D and other vitamin D metabolites, historically termed the "group-specific component" for its separately studied protein polymorphism (defined by the coding variants rs7041 and rs4588, which determine the classical Gc1F/Gc1S/Gc2 protein isoforms and affect DBP binding affinity independent of the regulatory signal discussed here). rs2282679 is a distinct, non-coding GC variant identified as the top genome-wide-significant locus for circulating 25(OH)D concentration in a meta-analysis of genome-wide association data from 33,996 individuals of European descent (Wang et al., 2010, Lancet; p=1.9x10^-109 for rs2282679), alongside independent signals near DHCR7 and CYP2R1. In that study, a combined genotype score across the three confirmed variants placed individuals in the top quartile at substantially higher odds of 25(OH)D below 75 nmol/L (OR 2.47, 95% CI 2.20-2.78) or below 50 nmol/L (OR 1.92, 95% CI 1.70-2.16) relative to the bottom quartile; this combined-score effect should not be attributed to rs2282679 in isolation. In a targeted case-control analysis of rs2282679 alone in an Iranian cohort (Asghari et al., 2023, BMC Endocr Disord), each copy of the minor (G) allele was associated with increased odds of vitamin D deficiency in an additive model (OR 1.35, 95% CI 1.06-1.73).
rs2282679 genotype is a modest, population-level modifier of measured 25(OH)D concentration, reflecting its role in vitamin D binding protein regulation and the resulting influence on the total (protein-bound plus free) 25(OH)D pool measured by standard assays. It is not diagnostic of vitamin D deficiency in an individual, does not substitute for direct 25(OH)D measurement, and behavioral/environmental determinants (sun exposure, adiposity, diet, malabsorption, medications) remain the dominant drivers of an individual's vitamin D status. No supplementation dosing recommendation follows from genotype at this locus.
What a 23andMe/AncestryDNA export or raw VCF can and can't tell you about Vitamin D Deficiency and the GC Gene comes down to these specific, well-studied positions — not a diagnosis.
It means your blood level of 25-hydroxyvitamin D, the main form measured in a standard test, falls below a defined threshold. Vitamin D helps your gut absorb calcium and phosphate for bone health, and low levels over time can contribute to weak or poorly mineralized bone.
They are answering different questions. The Institute of Medicine set thresholds for general population dietary adequacy and considers levels above 20 ng/mL sufficient for most people's bone health. The Endocrine Society's guideline is aimed at patients already known to be at risk and uses a stricter cutoff, calling levels below 30 ng/mL "insufficient." Both are legitimate, evidence-reviewed frameworks built for different purposes, which is why the same blood test result can be read differently.
No. This variant is associated with a modest downward shift in measured vitamin D levels and a somewhat higher statistical chance of testing as deficient, but it explains only a small part of the picture. Sun exposure, diet, body weight, and health conditions matter far more for any individual. A direct blood test is the only way to know your actual vitamin D status.
People with limited sun exposure (indoor lifestyles, high latitude, winter, covered skin, sunscreen use), older adults, people with obesity, people with conditions or surgeries that impair fat absorption, exclusively breastfed infants without supplementation, people with darker skin pigmentation living in temperate regions, and people with chronic kidney or liver disease or on certain anticonvulsant medications.
No. Genetic variants like this one only explain a small part of why vitamin D levels vary between people and cannot tell you your actual level. A direct blood test measuring 25-hydroxyvitamin D is the standard and only reliable way to assess an individual's vitamin D status.
Free to reuse. This page's text is original writing from freely-available research, licensed CC BY 4.0 — reuse it, including commercially, with attribution to MyGeneLog. It's general research-derived information, not medical advice or a diagnosis — see Terms of Use.